Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

merestinib (LY2801653)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Eli Lilly

Drug class:

c-MET inhibitor

Related drugs:

‹

›

TET2 L1231P	Acute Myelogenous Leukemia	TET2 L1231P	Acute Myelogenous Leukemia	LY2801653 Sensitive: C4 – Case Studies LY2801653 Sensitive : C4	LY2801653 Sensitive: C4 – Case Studies LY2801653 Sensitive : C4
TET2 E227	Acute Myelogenous Leukemia	TET2 E227	Acute Myelogenous Leukemia	LY2801653 Sensitive: C4 – Case Studies LY2801653 Sensitive : C4	LY2801653 Sensitive: C4 – Case Studies LY2801653 Sensitive : C4
NPM1 W288	Acute Myelogenous Leukemia	NPM1 W288	Acute Myelogenous Leukemia	LY2801653 Sensitive: C4 – Case Studies LY2801653 Sensitive : C4	LY2801653 Sensitive: C4 – Case Studies LY2801653 Sensitive : C4
DNMT3A R882H	Acute Myelogenous Leukemia	DNMT3A R882H	Acute Myelogenous Leukemia	LY2801653 Sensitive: C4 – Case Studies LY2801653 Sensitive : C4	LY2801653 Sensitive: C4 – Case Studies LY2801653 Sensitive : C4
FLT3 N676K	Acute Myelogenous Leukemia	FLT3 N676K	Acute Myelogenous Leukemia	LY2801653 Sensitive: C4 – Case Studies LY2801653 Sensitive : C4	LY2801653 Sensitive: C4 – Case Studies LY2801653 Sensitive : C4
ETV6-NTRK3 fusion	Squamous Cell Carcinoma of Head and Neck	ETV6-NTRK3 fusion	Squamous Cell Carcinoma of Head and Neck	LY2801653 Sensitive: D – Preclinical LY2801653 Sensitive : D	LY2801653 Sensitive: D – Preclinical LY2801653 Sensitive : D